Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting  Muscarinic Antagonist Combinations in Patients  with Chronic Obstructive Pulmonary Disease:  Meta-analysis of Phase 3 Randomized Trials

Pulmonary Disease ◽

Randomized Trials ◽

Meta Analysis ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Phase 3 ◽

Beta 2 ◽

Compare the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease

Tuberkuloz ve Toraks ◽

10.5578/tt.10778 ◽

2016 ◽

Vol 64 (2) ◽

pp. 112-118 ◽

Cited By ~ 2

Author(s):

Pınar SARAÇ ◽

Abdullah SAYINER

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Inhaled Steroids ◽

Beta 2 ◽

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s119908 ◽

2017 ◽

Vol Volume 12 ◽

pp. 367-381 ◽

Cited By ~ 17

Author(s):

James Donohue ◽

Keith Betts ◽

Ella Xiaoyan Du ◽

Pablo Altman ◽

Pankaj Goyal ◽

...

Keyword(s):

Pulmonary Disease ◽

Meta Analysis ◽

Chronic Obstructive ◽

Comparative Efficacy ◽

Beta 2 ◽

Comparison of Efficacy and Safety Outcomes in Randomized Trials of Long-Acting and Short-Acting Β2-Agonists for Chronic Obstructive Pulmonary Disease: A Review

Journal of Pulmonary & Respiratory Medicine ◽

10.4172/2161-105x.1000137 ◽

2013 ◽

Vol 03 (01) ◽

Author(s):

Vamsi K Bollu

Keyword(s):

Pulmonary Disease ◽

Randomized Trials ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Short Acting ◽

Safety Outcomes ◽

Long Acting ◽

Β2 Agonists

EFFICACY AND SAFETY OF ACETAZOLAMIDE FOR HYPERCAPNIC RESPIRATORY FAILURE ASSOCIATED WITH METABOLIC ALKALOSIS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A META-ANALYSIS OF RANDOMIZED TRIALS

Respirology ◽

10.1111/resp.13206_145 ◽

2017 ◽

Vol 22 ◽

pp. 59-59

Keyword(s):

Respiratory Failure ◽

Pulmonary Disease ◽

Metabolic Alkalosis ◽

Randomized Trials ◽

Meta Analysis ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Hypercapnic Respiratory Failure

Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s86002 ◽

2015 ◽

pp. 1673 ◽

Cited By ~ 2

Author(s):

Masakazu Ichinose ◽

Yoshinosuke Fukuchi ◽

Ayako Takizawa ◽

Toshiyasu Izumoto ◽

Yusuke Tadayasu ◽

...

Keyword(s):

Pulmonary Disease ◽

Japanese Patients ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Beta 2 ◽

Bayesian Network Meta-Analysis To Assess The Comparative Efficacy And Safety Of Treatments For Chronic Obstructive Pulmonary Disease

Value in Health ◽

10.1016/j.jval.2015.09.1383 ◽

2015 ◽

Vol 18 (7) ◽

pp. A495

Author(s):

V Taieb ◽

D Belhadi ◽

AT Nielsen ◽

M Hemels ◽

J Van Laer

Keyword(s):

Bayesian Network ◽

Pulmonary Disease ◽

Meta Analysis ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Comparative Efficacy ◽

Obstructive Pulmonary Disease

Combined Mometasone Furoate and Formoterol in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Phase 3 Efficacy and Safety Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2011.12.605 ◽

2012 ◽

Vol 129 (2) ◽

pp. AB75

Author(s):

D.E. Doherty ◽

E. Kerwin ◽

D.P. Tashkin ◽

C.E. Matiz-Bueno ◽

T. Shekar ◽

...

Keyword(s):

Pulmonary Disease ◽

Mometasone Furoate ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Safety Study ◽

Phase 3 ◽

Obstructive Pulmonary Disease

Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd006101 ◽

2006 ◽

Cited By ~ 10

Author(s):

Sarah Appleton ◽

Terry Jones ◽

Phillippa Poole ◽

Toby J Lasserson ◽

Robert Adams ◽

...

Keyword(s):

Pulmonary Disease ◽

Ipratropium Bromide ◽

Chronic Obstructive ◽

Beta 2 ◽

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease

Respiratory Medicine ◽

10.1016/j.rmed.2019.05.010 ◽

2019 ◽

Vol 153 ◽

pp. 38-43 ◽

Cited By ~ 14

Author(s):

James F. Donohue ◽

Edward Kerwin ◽

Sanjay Sethi ◽

Brett Haumann ◽

Srikanth Pendyala ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Phase 3 ◽

Once Daily ◽

Muscarinic Antagonist ◽

Correction:Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis

BMJ Open ◽

10.1136/bmjopen-2015-009183corr1 ◽

2019 ◽

Vol 9 (4) ◽

pp. e009183corr1

Keyword(s):

Systematic Review ◽

Pulmonary Disease ◽

Meta Analysis ◽

Chronic Obstructive ◽